Herspiegel Consulting is a full service brand management consulting firm that specializes in the pharmaceutical and biotech industry. We offer a range of integrative services, tailored and scaled to meet your brand and business’ needs across a wide variety of therapeutic areas. We ensure that critical problems are solved in a strategic manner and going above and beyond through implementation to seamless integration is what sets us apart.

Pharmaceutical New Product Planning capabilities

New Product Planning

Herspiegel Consulting delivers strategic assessments and structured processes to support critical business decisions for new products.

Pharmaceutical product launch capabilities


As an experienced launch partner, the Herspiegel Consulting team seamlessly integrates commercialization strategy with process expertise.

Pharmaceutical launch excellence capabilities


Marketing and brand management is at the core of all that Herspiegel Consulting does. We are experts at brand building and brand optimization.

Pharmaceutical commercial strategy capabilities

Market Access

Herspiegel Consulting has the proprietary intellectual assets and deep relationships with key opinion leaders to solve access challenges.

Pharmaceutical market shaping capabilities


Herspiegel Consulting has the expertise to effectively educate the market and change behaviors that are important to your brand.

Latest Blogs

The FDA approved Dupixent for moderate-to-severe atopic dermatitis

April 14, 2017
  The FDA approved Dupixent On March 28th, the FDA approved Dupixent for moderate-to-severe atopic ...
Read more

Why Drug Pricing is in the News Now and What Can Be Done About It?

March 3, 2017
Why drug pricing is in the news now and what can be done about it? From Turing Pharmaceuticals to Mylan,...
Read more

Key Challenges Facing Obamacare Repeal and Replace Plan

February 3, 2017
ACA repeal and replacement complicated by two key challenges...
Read more

How Pharma Can Prepare for the Patent Cliff

February 2, 2017
Extending market exclusivity and responding properly to the volume of recent patent expiries are critica...
Read more